Evolving Immuno-Oncology Strategies in Stage III NSCLC: A Focus on Recent Evidence and Key Next Steps in Trials

Release Date: August 30, 2021
Expiration Date: August 30, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck & Co, Inc.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists and cancer researchers involved in the care of patients with NSCLC. Other health care professionals involved in the study or treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the biology of tumor immunology and the scientific rationale for immune checkpoint inhibition in the management of stage III NSCLC.
• Integrate clinical trial evidence to optimize the use of immune checkpoint inhibitors in the treatment of patients with stage III NSCLC and describe ongoing studies investigating novel uses of immuno-oncology strategies
• Evaluate biomarkers for therapeutic selection in patients with NSCLC
• Discuss approaches to mitigate and manage the impact of immune-related adverse events in patients with NSCLC who receive immune checkpoint inhibitors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Karen L. Reckamp, MD, MS
Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Division of Medical Oncology
Department of Medicine
Cedars-Sinai Medical Center
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosures: Grant Research Support to prior institution: AbbVie, ACEA Therapeutics, Adaptimmune Therapeutics, Guardant Health, Molecular Partners, Seagen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Loxo Oncology, Spectrum Pharmaceuticals, Takeda Pharmaceutical, Xcovery, Zeno Pharmaceuticals, Calithera Biosciences, Daiichi Sankyo, Elevation Oncology; Consultant: Honararia to myself: Calithera, Euclises Pharmaceuticals, Guardant Health, Precision Health, Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Genentech, Janssen Pharmaceuticals, Lilly, Merck KGA, Seattle Genetics, Takeda Pharmaceuticals, Tesaro.

Christine A. Ciunci, MD, MSCE
Physician Lead of Cancer Service Line
Section Chief of Hematology Oncology
Associate Professor of Clinical Medicine
Abramson Cancer Center
Penn Presbyterian Medical Center
Philadelphia, PA

Disclosures: Christine A. Ciunci, MD, MSCE has no relevant financial relationships with ineligible companies.

Joel Neal, MD, PhD
Associate Professor of Medicine, Division of Oncology
Medical Director, Cancer Clinical Trials Office
Stanford Cancer Institute
Medical Director of Informatics
Stanford Cancer Center
Stanford, California

Disclosures: Grant/Research Support: Genentech/Roche, Merck & Co, Novartis Pharmaceuticals, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GlaxoSmithKline, Janssen Pharmaceuticals, AbbVie; Consultant: AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Co, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Medicines, Regeneron, Natera; Other Support: Up To Date–Royalties.

Jonathan Riess, MD, MS
Associate Professor of Hematology/Oncology
University of California, Davis, Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant/Research Support: Spectrum, AstraZeneca, Merck & Co, Novartis Pharmaceuticals, Revolution Medicine (all to institution); Consultant: Novartis Pharmaceuticals, EMD Serono, Genentech, Turning Point Therapeutics, Daiichi Sankyo, Boehringer Ingelheim.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.